Vericel Corp  

(Public, NASDAQ:VCEL)   Watch this stock  
Find more results for NASDAQ:ASTM
-0.14 (-3.93%)
Apr 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.24 - 3.55
52 week 2.55 - 5.39
Open 3.55
Vol / Avg. 166,800.00/152,435.00
Mkt cap 82.52M
P/E     -
Div/yield     -
EPS -3.19
Shares 23.79M
Beta 1.03
Inst. own 54%
May 13, 2015
Q1 2015 Vericel Corp Earnings Release (Estimated) Add to calendar
Apr 15, 2015
Vericel Corp at Needham Healthcare Conference
Mar 24, 2015
Vericel Corp at Canaccord Genuity Musculoskeletal Conference
Mar 23, 2015
Q4 2014 Vericel Corp Earnings Call - Webcast
Mar 23, 2015
Q4 2014 Vericel Corp Earnings Release
Mar 11, 2015
Vericel Corp at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -16.12% -69.18%
Operating margin -15.95% -81.73%
EBITD margin - -62.28%
Return on average assets -19.41% -70.15%
Return on average equity - -
Employees 190 -
CDP Score - -


64 Sidney St
CAMBRIDGE, MA 02139-4170
United States - Map
+1-734-9305555 (Phone)
+1-734-6650485 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc., is a clinical-stage biotechnology company. The Company develops patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues. It markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant product for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), an autologous permanent skin replacement for the treatment of severe burns. Vericel also develops MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy(DCM).

Officers and directors

Robert L. Zerbe M.D. Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Dominick C. Colangelo President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Gerard J. Michel Chief Financial Officer, Vice President - Corporate Development
Age: 51
Bio & Compensation  - Reuters
Daniel R. Orlando Chief Operating Officer, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Ross Tubo Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
David Recker M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Steven C. Gilman Ph.D. Director
Age: 62
Bio & Compensation  - Reuters
Heidi Hagen Director
Age: 46
Bio & Compensation  - Reuters
Kevin F. McLaughlin Director
Bio & Compensation  - Reuters
Paul K. Wotton Ph.D. Director
Age: 54
Bio & Compensation  - Reuters